| ［1］ Folkman J. Tumor angiogenesis: therapeutic implications. Engl N J Med, 1971, 285(21): 1182 1186.
［2］Carmeliet P, Jain R K. Angiogenesis in cancer and other diseases. Nature, 2000, 407(6801): 249 257.
［3］ Folkman J, Kalluri R. Cancer without disease. Nature, 2004, 427(6977): 787.
［4］ Naumov G N, Folkman J, Straume O. Tumor dormancy due to failure of angiogenesis. Clin Ex PMetastasis, 2009, 26(1): 51 60.
［5］ Folkman J, Shing Y. Angiogenesis. J Biol Chem, 1992, 267(16): 10931 10934.
［6］ Folkman J. Angiogenesis dependent diseases. Semin Oncol, 2001, 28(6): 536 542.
［7］ Kilarski W W, Gerwins P. A new mechanism of blood vessel growth hope for new treatment strategies. Discov Med, 2009, 8(40): 23 27.
［8］ Cooke V G, Kalluri R. Molecular mechanism of type IV collagenderived endogenous inhibitors of angiogenesis. Methods Enzymol, 2008,444:1 19.
［9］ Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res, 2005, 65(10): 3967 3979.
［10］ Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov, 2007, 6(4): 273 286.
［11］ Otrock Z K, Mahfouz R A, Makarem J A, et al. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis, 2007, 39(2): 212 220.
［12］ Sund M, Hamano Y, Sugimoto H, et al. Function of endogenous inhibitors of angiogenesis as endothelium specific tumor suppressors . Proc Natl Acad Sci USA, 2005, 102(8): 2934 2939.
［13］ Tsang K Y, Cheung M C, Chan D, et al. The developmental roles of the extracellular matrix: beyond structure to regulation. Cell and Tissue Res, 2010,339(1):93110.
［14］ Rozario T, DeSimone D W. The extracellular matrix in development and morphogenesis: A dynamic view. Dev Biol, 2010,341(1):126140.
［15］ Bauer A L, Jackson T L, Jiang Y. Topography of extracellular matrix mediates vascular morphogenesis and migration speeds in angiogenesis. PLoS Comput Biol, 2009,5(7): e1000445.
［16］ Eduard M D, Akmal M D, Vachtang M D, et al. Promotion of tumor cell migration by extracellular matrix proteins in human pancreatic cancer . Pancreas, 2009, 38(7): 804 810.
［17］ Kalluri R. Discovery of type Ⅳ collagen noncollagenous domains as novel integrin ligands and endogenous inhibitors of angiogenesis. Cold Spring Harb Sym PQuant Biol, 2002, 67: 255 266.
［18］ Sugimoto M, Oohashi T, Ninomia Y. The genes COL4A5 and COL4A6, coding for the basement membrane collagen chains α5(IV) and α6(IV), are located head to head in close proximity on human chromosome Xq22 and COL4A6 is transcribed from two alternative promoters. Proc Natl Acad Sci USA, 1994, 91(24): 11679 11683.
［19］ Colorado P C, Torre A, Kamphaus G, et al. Anti angiogenic cues from vascular basement membrane collagen. Cancer Res, 2000, 60(9): 2520 2526.
［20］ Sudhakar A, Nyberg P, Keshamouni V G, et al. Human α1 type Ⅳ collagen NC1 domain exhibits distinct antiangiogenic activity mediated by α1β1 integrin. J Clin Invest, 2005, 115(10): 2801 2810.
［21］ Kamphaus G D, Colorado P C, Panka D J, et al. Canstatin, a novel matrix derived inhibitor of angiogenesis and tumor growth. J Biol Chem, 2000, 275(2): 1209 1215.
［22］ Panka D J, Mier J W. Canstatin inhibits Akt activation and induces Fas dependent apoptosis in endothelial cells. J Biol Chem, 2003, 278(39): 37632 37636.
［23］ Magnon C, Galau P A, Mullan B, et al. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with αvβ3 and αvβ5 integrins. Cancer Res, 2005, 65(10): 4353 4361.
［24］ Maeshima Y, Colorado P C, Torre A, et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem, 2000, 275(28): 21340 21348.
［25］ Maeshima Y, Colorado P C, Kalluri R.Two RGD independent αvβ3 integrin binding sites on tumstatin regulate distinct anti tumor properties. J Biol Chem, 2000, 275(31): 23745 23750.
［26］ Maeshima Y, Yerramalla U L, Dhanabal M, et al. Extracellular matrix derived peptide binds to αvβ3 integrin and inhibits angiogenesis. J Biol Chem, 2001, 276(34): 31959 31968.
［27］ Maeshima Y, Sudhakar A, Lively J C, et al. Tumstatin, an endothelial cell specific inhibitor of protein synthesis. Science, 2002, 295(5552): 140 143.
［28］ Sudhakar A, Boosani C S. Inhibition of tumor angiogenesis by tumstatin: insights into signaling mechanisms and implications in cancer regression. Pharm Res, 2008, 25(12): 2731 2739.
［29］ Boosani C S, Mannam A P, Cosqrove D, et al. Regulation of COX 2 mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis. Blood, 2007, 110(4): 1168 1177.
［30］ 温镭，贺欣，赵启仁,等．新型肿瘤血管生成抑制剂hexastatin的研究进展．中国肿瘤生物治疗杂志，2009,16(5):537 540. Wen L, He X, Zhao Q R, et al. Chinese Journal of Cancer Biotherapy, 2009,16(5): 537 540.
［31］ Karagiannis E D, Popel A S. Identification of novel short peptides derived from the α4, α5, and α6 fibrils of type IV collagen with anti angiogenic properties. Biochem Biophys Res Commun, 2007,354(2): 434 439.
［32］ Petitclerc E, Boutaud A, Prestayko A, et al. New functions for non collagenous domains of human collagen: type IV novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem, 2000, 275(11): 8051 8061.
［33］ Baba Y, Iyama K, Ikeda K, et al. Differential expression of basement membrane type IV collagen α chains in gastric intramucosal neoplastic lesions. J Gastroenterol, 2007, 42(11): 874 880.
［34］ Nyberq P, Xie L, Suqimoto H, et al. Characterization of the anti angiogenic properties of arresten, an α1β1 integrin dependent collagenderived tumor suppressor. Exp Cell Res, 2008, 314(18): 3292 3305.
［35］ Long M Y, Li H H, Xu J Y, et al. Inhibitory effects of transfection of arresten gene on liver metastasis from colorectal cancer in nude mice. Ai Zheng, 2008, 27(10): 1039 1043.
［36］ Narazaki M, Tosato G. Canstatin: an inhibitor of angiogenesis and tumor growth revisited. Cancer J, 2006, 12(2): 110 112.
［37］ Lee J H, Lee J M, Jeon H B, et al. Expression and in vitro activity of recombinant canstatin in stably transformed bombyx mori cells. J Microbiol Biotechnol, 2009, 19(7): 685 689.
［38］ Wang W B, Zhou Y L, Heng D F, et al. Combination of tumor necrosis factor related apoptosis inducing ligand(TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice. Breast Cancer Res Treat, 2008, 110(2): 283 295.
［39］ Zheng X W, Li Y, Tang F A, et al. In vivo antitumor effect of canstatin gene on human esophageal carcinoma xenografts in nude mice. Ai Zheng, 2009, 28(4): 350 355.
［40］ Magnon C, Opolon P, Connault E, et al. Canstatin gene electrotransfer combined with radiotherapy: preclinical trials for cancer treatment. Gene Ther, 2008, 15(21): 1436 1445.
［41］ Hamano Y, Kalluri R. Tumstatin, the NC1 domain of α3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem Biophys Res Commun, 2005, 333(2): 292 298.
［42］ Caudroy S, Cucherousset J, Lorenzato M, et al. Implication of tumstatin in tumor progression of human bronchopulmonary carcinomas. Human Pathol, 2004, 35(10): 1218 1222.
［43］ Pasco S, Brassart B, Ramont L, et al. Control of melanoma cell invasion by type IV collagen. Cancer Detect Prevent, 2005, 29(3): 260 266.
［44］ Kawaguchi T, Yamashita Y, Kanamori M, et al. The PTEN/Akt pathway dictates the direct αvβ3 dependent growth inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res, 2006, 66(23): 11331 11340.
［45］ Zhang X, Xu W, Qian H, et al. Mesenchymal stem cells modified to express lentivirus TNFα Tumstatin45 132 inhibit the growth of prostate cancer. J Cell Mol Med, in Press.
［46］ Chung I S, Son Y I, Ko Y J, et al. Peritumor injections of purified tumstatin delay tumor growth and lymphatic metastasis in an orthotopic oral squamous cell carcinoma model. Oral Oncol, 2008, 44(12): 1118 1126.
［47］ Maeshima Y, Manfredi M, Reimer C, et al. Identification of the antiangiogenic site within vascular basement membrane derived tumstatin. J Biol Chem, 2001, 276(18): 15240 15248.
［48］ Eikesdal H P, Sugimoto H, Birrane G, et al. Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity. Proc Natl Acad Sci USA, 2008, 105(39): 15040 15045.
［49］ Zhang G M, Zhang Y M, Fu S B, et al.Effects of cloned tumstatin related and angiogenesis inhibitory peptides on proliferation and apoptosis of endothelial cells. Chin Med J, 2008, 121(22): 2324 2330.
［50］ Li Y J, Sun L C, He Y, et al. The anti tumor properties of two tumstatin peptide fragments in human gastric carcinoma. Acta Pharmacol Sin, 2009, 30(9): 1307 1315.
［51］ Zhou J, Mochizuki T, Smeets H, et al. Deletion of the paired α5(IV) and α6(IV) collagen genes in inherited smooth muscle tumors. Science, 1993, 261(5125): 1167 1169.
［52］ Mundel T M, Yliniemi A M, Maeshima Y, et al. Type IV collagen α6 chain derived noncollagenous domain 1 (α6(IV)NC1) inhibits angiogenesis and tumor growth. Int J Cancer, 2008, 122(8): 1738 1744.
［53］ Baba Y, Iyama K, Ikeda K, et al. The expression of type IV collagen α6 chain is related to the prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol, 2008, 15(2): 555 565.
［54］ Ikeda K, Iyama K, Ishikawa N, et al. Loss of expression of type IV collagen α5 and α6 chains in colorectal cancer associated with the hypermethylation of their promoter region. Am J Pathol, 2006, 168(3): 856 865.
［55］ Misumi S, Iyama K, Honda Y, et al. Differential expression of basement membrane type IV collagen α1, α2, α5 and α6 chains among the histological subtypes of adenoid cystic carcinoma. Virchows Arch, 2004, 445(1): 54 62.
［56］ Stommel J M, Kimmelman A C, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 2007, 318(5848): 287 290. |
